Lentivirus-mediated sFlt-1 gene fragment transfer suppresses retinal neovascularization

Current Eye Research

Volumn 34, Issue 5, 2009, Pages 401-410

  Min, Zhang ^a   Qiang, Wu ^a   Benwen, Song ^a   Bin, Lu ^a   Xinhua, Du ^a  

^a Shanghai No 6 People's Hospital   (China)

Author keywords

Gene transfer; Retinal neovascularization; SFlt 1; VEGF

Indexed keywords

ALPHA CRYSTALLIN; ANNEXIN; BETA CRYSTALLIN; BIOLOGICAL MARKER; CASPASE 12; CATENIN; CELL PROTEIN; CRYSTALLIN; CYTOKERATIN 16; EPHRIN RECEPTOR A4; ETHYLNITROSOUREA; FORMIN 2; GAMMA GLUTAMYLTRANSFERASE; GAP JUNCTION MEMBRANE CHANNEL PROTEIN ALPHA 3; GAP JUNCTION MEMBRANE CHANNEL PROTEIN ALPHA 9; GLUTATHIONE SYNTHASE; HEAT SHOCK PROTEIN; KRUPPEL LIKE FACTOR; LIPOCORTIN 4; NEOGENIN; SOMATOMEDIN BINDING PROTEIN 4; SRY BOX CONTAINING 1; SRY BOX CONTAINING 30; SYNDECAN 1; T BOX 20; UNCLASSIFIED DRUG; VISUAL SYSTEM HOMEOBOX 1; OXYGEN; PEPTIDE FRAGMENT; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATARACT; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; DISEASE MODEL; DNA MICROARRAY; GAP JUNCTION; GENE IDENTIFICATION; GENE LOCATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; IMMUNOHISTOCHEMISTRY; LENS; LENS EPITHELIUM; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PERINATAL PERIOD; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; TWO DIMENSIONAL ELECTROPHORESIS; WILD TYPE; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; FLUORESCENCE ANGIOGRAPHY; GENE TRANSFER; GENE VECTOR; GENETICS; ISCHEMIA; LENTIVIRINAE; METABOLISM; NEWBORN; RETINA BLOOD VESSEL; RETINA NEOVASCULARIZATION; WESTERN BLOTTING;

ANIMALS; ANIMALS, NEWBORN; BLOTTING, WESTERN; FLUORESCEIN ANGIOGRAPHY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; IMMUNOHISTOCHEMISTRY; ISCHEMIA; LENTIVIRUS; MICE; OXYGEN; PEPTIDE FRAGMENTS; RETINAL NEOVASCULARIZATION; RETINAL VESSELS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 67649635556     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.1080/02713680902862971     Document Type: Article

References (40)

1. Lee P, Wang CC, Adamis AP. Ocular neovascularization: An epidemiological review. Surv Ophthalmol. 1998;43:245-269.
2. Steinkuller PG, Du L, Gilbert C, et al. Childhood blindness. J AAPOS. 1999;3:26-32.
3. Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct. 2001;26:25-35.
4. Barleon B, Totzke F, Herzog C, et al. Mapping for the sites of ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor Flt-1. J Biol Chem. 1997;272:10382-10388.
5. Smith LE, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35:101-111.
6. Lyle WM, Cullen AP, Charman WN. Role of lasers in eye care. Optom Vis Sci. 1993;70:136-151.
7. Reynolds JD. The management of retinopathy of prematurity. Paediatr Drugs. 2001;3:263-272.
8. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med. 1999;77:527-543.
9. Aiello LP. Vascular endothelial growth factor and the eye: Biochemical mechanisms of action and implications for novel therapies. Ophthalmic Res. 1997;29:354-362.
10. Ozaki H, Seo MS, Ozaki K, et al. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am J Pathol. 2000;156:697-707.
11. Ferrara N, Houck K, Jakeman L, et al. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev. 1992;13:18-32.
12. Jakeman LB, Winer J, Bennett GL,etal. Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J Clin Invest. 1992;89:244-253.
13. Senger DR, Perruzzi CA, Feder J, et al. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res. 1986;46:5629-5632.
14. Thieme H, Aiello LP, Takagi H, et al. Comparative analysis of vascular endothelial growth factor receptors on retinal and aortic vascular endothelial cells. Diabetes. 1995;44:98-103.
15. Sydorova M, Lee MS. Vascular endothelial growth factor levels in vitreous and serum of patients with either proliferative diabetic retinopathy or proliferative vitreoretinopathy. Ophthalmic Res. 2005;37:188-190.
16. Ohno-Matsui K, Hirose A, Yamamoto S, et al. Inducible expression of vascular endothelial growth factor in adult mice causes severe proliferative retinopathy and retinal detachment. Am J Pathol. 2002;l60:711-719.
17. Villegas-Becerril E, Gonzalez-Fernandez R, Fernandez-Molina F, et al. Growth factor levels and ROP. Ophthalmology. 2005;112:2238.
18. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA. 1995;92:10457-10461.
19. Ideno J, Mizukami H, Kakehashi A, et al. Prevention of diabetic retinopathy by intraocular soluble flt-1 gene transfer in a spontaneously diabetic rat model. Int J Mol Med. 2007;19:75-79.
20. Bainbridge JW, Mistry A, De Alwis M, et al. Inhibition of retinal neovascularization by gene transfer of soluble VEGF receptor sFlt-1. Gene Ther. 2002;9:320-326.
21. Fantl WJ, Johnson DE, Williams LT. Signaling by receptor tyro-sine kinases. Annu Rev Biochem. 1993;62:453-481.
22. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular en-dothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA. 1995;92:10457-10461.
23. Goldman CK, Kendall RL, Cabrera G, et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA. 1995;95:8795-8800.
24. Hasumi Y, Mizukami H, Urabe M, et al. Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer. Cancer Res. 2002;62:2019-2023.
25. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA. 1993;90:10705-10709.
26. Kong HL, Hecht D, Song W, et al.Regional suppressionoftumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor. Hum Gene Ther. 1998;9:823-833.
27. Shiose S, Sakamoto T, Yoshikawa H, et al. Gene transfer of a soluble receptor of VEGF inhibits the growth of experimental eyelid malignant melanoma. Invest Ophthalmol Vis Sci. 2000;41:2395-2403.
28. Lai CM, Brankov M, Zaknich T, et al. Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization. 2002;75:625-634.
29. Kendall RL, Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun. 1996;226:324-328.
30. Blechman JM, Lev S, Barg J, et al. The fourth immunoglobulin domain of the stem cell factor receptor couples ligand binding to signal transduction. Cell. 1995;80:103-113.
31. Vigna E, Naldini L. Lentiviral vectors: Excellent tools for experimental gene transfer and promising candidates for gene therapy. J Gene Med. 2000;2:308-316.
32. Bartoseh B, Cosset FL. Strategies for retargeted gene delivery using vectors derived from lentiviruses. Curr Gene Ther. 2004;4:427-443.
33. Brun S, Faucon-Biguet N, Mallet J. Optimization of transgene expression at the posttranscriptional level in neural cells: implications for gene therapy. Mol Ther. 2003;7:782-789.
34. Hawley RG. Progress toward vector design for hematopoietic stem cell gene therapy. Curr Gene Ther. 2001; 1:1-17.
35. Leurs C, Jansen M, Pollok KE, et al. Comparison of three retrovi-ral vector systems for transduction of nonobese diabetic/severe combined immunodeficiencymice repopulating humanCD34+ cord blood cells. Hum Gene Ther. 2003;14:509-519.
36. Engerman RL. Animal models of diabetic retinopathy. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol. 1976;81:OP710-OP715.
37. Pierce EA, Avery RL, Foley ED, et al. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA. 1995;92:905-909.
38. Singh N, Amin S, Richter E, et al. Flt-1 intraceptors inhibit hypoxia-induced VEGF expression in vitro and corneal neovas-cularization in vivo. Invest Ophthalmol Vis Sci. 2005;46:1647-1652.
39. Barleon B, Siemeister G, Maritny-Baron G, et al. Vascular en-dothelial growth factor up-regulates its receptor fms-like tyro-sine kinase 1 (FLT-1) and a soluble variant of FLT-1 in human vascular endothelial cells. Cancer Res. 1997;57:5421-5425.
40. Kremer C, Breier G, Risau W, et al. Up-regulation of flk-1/vascular endothelial growth factor receptor 2 by its ligand in a cerebral slide culture system. Cancer Res. 1997;57:3852-3859.